Convalescent plasma doesnt benefit severely ill patients hospitalized with COVID-19, study shows08/07/2022
Convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover, according to a national clinical trial led by Vanderbilt University Medical Center and published in the journal CHEST.
The multicenter blinded, randomized placebo-controlled, Passive Immunity Trial for our Nation (PassITON), looked at the efficacy and safety of COVID-19 convalescent plasma therapy for adults hospitalized with moderate to severe COVID-19 within 14 days of the onset of symptoms.
The rationale for using convalescent plasma for acute viral infections like COVID-19 has been that transfusing the plasma component of blood from a patient who has recently recovered from the same disease to a patient early in the stage of infection might provide the currently infected patient with antibodies against the infecting virus, helping them recover more quickly.
“During this trial, we were fortunate to have tremendous collaboration among thousands of people across the country, including patients, families, clinicians, study personnel at 25 hospitals and a wonderful team at VUMC,” said Wesley Self, MD, MPH, associate professor of Emergency Medicine, vice president for Clinical Research Networks and Strategy at VUMC and lead author of the study. “We asked a very specific question in this study: At time of hospital admission when a patient is severely ill with COVID, does the transfusion of convalescent plasma available to clinicians in the U.S. improve the ability to recover and survive? The answer is clearly no.”
“Providing passive immunity with convalescent plasma does not appear to benefit patients once their illness has progressed to the point of needing treatment in the hospital. Despite receiving convalescent plasma with a higher titer of neutralizing antibodies, the therapy did not help hospitalized patients,” said Todd Rice, MD, MSc, associate professor of Medicine, vice president for Clinical Trial Innovations and Operations at VUMC, and senior author of the study.
In the study 960 adults hospitalized with COVID-19 were randomized into two groups — those receiving one unit of convalescent therapy and those receiving placebo. The results showed that the two groups had nearly identical clinical outcomes; at 28 days following treatment, 18.5% of patients in the convalescent plasma group and 17.2% of patients in the placebo group had died.
Source: Read Full Article